X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (2054) 2054
Newsletter (558) 558
Publication (103) 103
Book Review (50) 50
Magazine Article (19) 19
Book Chapter (8) 8
Newspaper Article (4) 4
Conference Proceeding (2) 2
Trade Publication Article (2) 2
Book / eBook (1) 1
Data Set (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
adalimumab (2130) 2130
humans (1180) 1180
index medicus (949) 949
infliximab (948) 948
pharmacology & pharmacy (734) 734
tumor necrosis factor-alpha - antagonists & inhibitors (569) 569
etanercept (548) 548
female (531) 531
male (519) 519
immunotherapy (507) 507
research (443) 443
adult (438) 438
care and treatment (428) 428
rheumatoid arthritis (423) 423
middle aged (410) 410
drug therapy (388) 388
antibodies, monoclonal - therapeutic use (387) 387
medical research (349) 349
psoriasis (346) 346
treatment outcome (342) 342
tumor necrosis factor (334) 334
medicine, experimental (327) 327
arthritis (319) 319
arthritis, rheumatoid - drug therapy (303) 303
antibodies, monoclonal, humanized (302) 302
antirheumatic agents - therapeutic use (276) 276
rheumatoid-arthritis (273) 273
therapy (267) 267
double-blind (252) 252
rheumatoid factor (250) 250
crohn's disease (247) 247
efficacy (235) 235
complications and side effects (232) 232
risk factors (231) 231
medicine & public health (227) 227
crohns-disease (221) 221
gastroenterology & hepatology (221) 221
methotrexate (220) 220
antibodies, monoclonal, humanized - therapeutic use (215) 215
rheumatology (211) 211
analysis (208) 208
inflammatory-bowel-disease (208) 208
aged (201) 201
antibodies, monoclonal - pharmacology (201) 201
monoclonal antibodies (199) 199
pharmacology/toxicology (199) 199
ulcerative colitis (194) 194
dosage and administration (192) 192
safety (190) 190
adalimumab - therapeutic use (179) 179
crohn disease - drug therapy (176) 176
dermatology (175) 175
psoriasis - drug therapy (172) 172
anti-inflammatory agents - therapeutic use (171) 171
inflammatory bowel disease (171) 171
reports (170) 170
animals (164) 164
antibodies, monoclonal - adverse effects (161) 161
immunoglobulin g - therapeutic use (161) 161
receptors, tumor necrosis factor - therapeutic use (161) 161
case studies (160) 160
tumor necrosis factor-tnf (155) 155
immunology (152) 152
patients (149) 149
biological products (147) 147
gastrointestinal diseases (143) 143
antirheumatic agents - pharmacology (141) 141
antibodies (138) 138
medicine, research & experimental (136) 136
diagnosis (132) 132
young adult (131) 131
patient outcomes (128) 128
certolizumab pegol (127) 127
health aspects (126) 126
adalimumab, adverse reactions (125) 125
retrospective studies (123) 123
clinical trials (119) 119
severity of illness index (119) 119
tumor-necrosis-factor (119) 119
internal medicine (114) 114
psoriatic arthritis (114) 114
monoclonal-antibody (112) 112
tumors (112) 112
placebo-controlled trial (111) 111
tumor necrosis factor-alpha - immunology (109) 109
adalimumab, adverse reactions - serious (108) 108
pharmacology (106) 106
adalimumab - pharmacology (105) 105
antibodies, monoclonal, humanized - pharmacology (104) 104
disease (104) 104
remission (104) 104
adolescent (103) 103
immunogenicity (103) 103
inflammation (102) 102
necrosis-factor-alpha (102) 102
antirheumatic agents - adverse effects (100) 100
inflammatory bowel diseases - drug therapy (100) 100
cytokines (99) 99
immunoglobulin g - pharmacology (98) 98
tnf-alpha (97) 97
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2579) 2579
Spanish (23) 23
French (12) 12
Italian (10) 10
German (7) 7
Japanese (5) 5
Hungarian (4) 4
Russian (4) 4
Croatian (1) 1
Polish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


British Journal of Pharmacology, ISSN 0007-1188, 08/2015, Volume 172, Issue 15, pp. 3805 - 3816
Journal Article
Drug Metabolism and Disposition, ISSN 0090-9556, 07/2016, Volume 44, Issue 7, pp. 924 - 933
Journal Article
Pharmaceutical Research, ISSN 0724-8741, 2/2018, Volume 35, Issue 2, pp. 1 - 11
To measure aggregate and particle formation in tumor necrosis factor-alpha (TNF-α) inhibitors etanercept, adalimumab and certolizumab pegol product samples... 
Biochemistry, general | Biomedical Engineering | Biomedicine | drug product characterization | home storage | Pharmacy | Medical Law | Pharmacology/Toxicology | aggregation of antibodies | freezing stress conditions | TNF-α inhibitors | IMMUNOGENICITY | PRODUCT | TNF-alpha inhibitors | PHARMACOLOGY & PHARMACY | MONOCLONAL-ANTIBODY | CHEMISTRY, MULTIDISCIPLINARY | Protein Aggregates | Anti-Inflammatory Agents - pharmacology | Adalimumab - chemistry | Certolizumab Pegol - chemistry | Chemistry, Pharmaceutical | Particle Size | Etanercept - chemistry | Certolizumab Pegol - pharmacology | Anti-Inflammatory Agents - chemistry | Etanercept - pharmacology | Adalimumab - pharmacology | Drug Storage - standards | Freezing - adverse effects | Biological Factors - chemistry | Biological Factors - pharmacology | Tumor Necrosis Factor-alpha - antagonists & inhibitors | Viral antibodies | Biological products | Tumor necrosis factor | Antibodies | Drug therapy | Tumors | Necrosis | Drugs | Size exclusion chromatography | Temperature | Freeze thaw cycles | Storage temperature | Thawing | Photon correlation spectroscopy | Freezing | Nanoparticles | Etanercept | Temperature effects | Spectrum analysis | Tumor necrosis factor-TNF | Freeze-thawing | Spectroscopy | Alpha rays | Light scattering | Tumor necrosis factor-α | Patients | High pressure | Inhibitors | Storage | Storage conditions | Packaging | Monoclonal antibodies | Research Paper
Journal Article
Drug Development Research, ISSN 0272-4391, 11/2014, Volume 75, Issue 1, pp. S77 - S80
Postmarketing Phase IV Patients with active rheumatoid arthritis (RA) frequently show an atherogenic lipid profile, which has been linked with the inflammatory... 
clinical response | disease activity | anti‐tumor necrosis factor alpha | rheumatoid arthritis | lipid profile | Lipid profile | Disease activity | Clinical response | Rheumatoid arthritis | Anti-tumor necrosis factor alpha | CHEMISTRY, MEDICINAL | THERAPY | anti-tumor necrosis factor alpha | PHARMACOLOGY & PHARMACY | MECHANISMS | TNF-ALPHA | Hydroxychloroquine - therapeutic use | Methotrexate - pharmacology | Certolizumab Pegol | Arthritis, Rheumatoid - blood | Cyclosporine - pharmacology | Cholesterol - blood | Humans | Middle Aged | Antibodies, Monoclonal - therapeutic use | Male | Sulfasalazine - pharmacology | Immunoglobulin Fab Fragments - therapeutic use | Methotrexate - therapeutic use | Adrenal Cortex Hormones - therapeutic use | Polyethylene Glycols - therapeutic use | Receptors, Tumor Necrosis Factor - therapeutic use | Etanercept | Infliximab | Arthritis, Rheumatoid - drug therapy | Antibodies, Monoclonal, Humanized - pharmacology | Immunoglobulin G - pharmacology | Adult | Female | Aspirin - therapeutic use | Antirheumatic Agents - pharmacology | Aspirin - pharmacology | Drug Therapy, Combination | Antirheumatic Agents - therapeutic use | Polyethylene Glycols - pharmacology | Severity of Illness Index | Sulfasalazine - therapeutic use | Antibodies, Monoclonal, Humanized - therapeutic use | Antibodies, Monoclonal - pharmacology | Adrenal Cortex Hormones - pharmacology | Immunoglobulin G - therapeutic use | Treatment Outcome | Immunoglobulin Fab Fragments - pharmacology | Cyclosporine - therapeutic use | Lipid Metabolism - drug effects | Triglycerides - blood | Hydroxychloroquine - pharmacology | Aged | Adalimumab | Tumor Necrosis Factor-alpha - antagonists & inhibitors | Drugs | Medical research | Rheumatoid factor | Antirheumatic agents | Corticosteroids | Tumor necrosis factor | Atherosclerosis | Medicine, Experimental | Arthritis | Drug therapy | Tumors | Necrosis | Lipids | Metabolism | Cholesterol
Journal Article
Scandinavian Journal of Gastroenterology, ISSN 0036-5521, 2009, Volume 44, Issue 7, pp. 774 - 781
Antibody constructs targeting tumour necrosis factor-alpha (TNF) have become important in the management of several chronic immunoinflammatory diseases. Four... 
biotherapy | personal medicine | pharmacodynamics | therapy | Anti-drug antibodies (ADA) | pharmacokinetics | Crohn's disease | individual medicine | ulcerative colitis | immunogenicity | Therapy | Pharmacodynamics | Biotherapy | Immunogenicity | Personal medicine | Pharmacokinetics | Individual medicine | Ulcerative colitis | RHEUMATOID-ARTHRITIS | MAINTENANCE TREATMENT | CROHNS-DISEASE | ADALIMUMAB | SERUM INFLIXIMAB | RANDOMIZED-TRIAL | MONOCLONAL-ANTIBODY | GASTROENTEROLOGY & HEPATOLOGY | CLINICAL-RESPONSE | ANTI-INFLIXIMAB ANTIBODIES | FUSION PROTEINS | Immunotherapy - methods | Certolizumab Pegol | Humans | Inflammatory Bowel Diseases - immunology | Biological Availability | Antibodies, Monoclonal, Humanized | Etanercept | Infliximab | Radioimmunoassay | Tumor Necrosis Factor-alpha - immunology | Antibodies - immunology | Immunoglobulin G - pharmacology | Anti-Inflammatory Agents - pharmacokinetics | Gastrointestinal Agents - pharmacokinetics | Polyethylene Glycols - pharmacology | Inflammatory Bowel Diseases - drug therapy | Anti-Inflammatory Agents - pharmacology | Antibodies, Monoclonal - pharmacology | Antibodies, Monoclonal - pharmacokinetics | Polyethylene Glycols - pharmacokinetics | Immunoglobulin Fab Fragments - pharmacology | Antibodies - pharmacology | Gastrointestinal Agents - pharmacology | Receptors, Tumor Necrosis Factor | Adalimumab | Tumor Necrosis Factor-alpha - antagonists & inhibitors
Journal Article
BioDrugs, ISSN 1173-8804, 12/2016, Volume 30, Issue 6, pp. 525 - 570
Journal Article
BioDrugs, ISSN 1173-8804, 8/2016, Volume 30, Issue 4, pp. 339 - 351
Journal Article
Gastroenterology, ISSN 0016-5085, 2011, Volume 141, Issue 6, pp. 2026 - 2038
Journal Article
Journal Article